Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes

Authors Brooks GD

Received 31 August 2019

Accepted for publication 16 February 2020

Published 4 March 2020 Volume 2020:16 Pages 181—187

DOI https://doi.org/10.2147/TCRM.S192392

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


G Daniel Brooks

The Asthma and Allergy Center, Bellevue, NE, USA

Correspondence: G Daniel Brooks
The Asthma and Allergy Center, 3503 Samson Way, Suite 108, Bellevue, NE 68123, USA
Tel +1-402-592-2055
Fax +1-402-592-2419
Email gdbrooks@asthmaandallergycenter.com

Abstract: Uncontrolled asthma continues to be a problem for many patients with moderate-to-severe allergic asthma. Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticosteroid use. When selecting patients for dupilumab, it is important to consider entry criteria for the original studies, subgroups that have responded best, and the presence of comorbid diseases that may also respond to dupilumab. Factors that were considered when selecting patients likely to respond to dupilumab in asthma studies include: failure of moderate or high dose inhaled steroids in combination with an additional controller medication, baseline FEV1 reversibility of 12% or greater, and Asthma Control Questionnaire > 1.5. The baseline characteristics that predicted a better response to dupilumab included blood eosinophils > 150 cells/mm3 and fractional exhaled nitric oxide > 25 parts per billion. Comorbidities that may also respond to treatment with dupilumab include atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis. A combination of these factors should be considered when selecting the patients most likely to benefit from dupilumab.

Keywords: allergic asthma, dupilumab, eosinophils, nitric oxide, comorbidity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]